603983.SS
Guangdong Marubi Biotechnology Co., Ltd. [603983.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
603983.SS Stock Summary
Top 10 Correlated ETFs
603983.SS
Top 10 Correlated Stocks
603983.SS
In the News
603983.SS Financial details
Company Rating
Neutral
Market Cap
11.02B
Income
228M
Revenue
2.12B
Book val./share
8.13
Cash/share
3.1
Dividend
0.25
Dividend %
0.87%
Employees
1.06K
Optionable
No
Shortable
Yes
Earnings
27 Apr 2024
P/E
53.02
Forward P/E
-
PEG
-82.18
P/S
5.42
P/B
3.71
P/C
8.91
P/FCF
364.8
Quick Ratio
1.93
Current Ratio
2.9
Debt / Equity
0.08
LT Debt / Equity
0
-
-
EPS (TTM)
0.58
EPS next Y
-
EPS next Q
-
EPS this Y
-30.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-17.86%
Revenue last 5Y
1.91%
Revenue Q/Q
-18.13%
EPS Q/Q
-15.38%
-
-
-
-
SMA20
-9.68%
SMA50
-3.45%
SMA100
3.7%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
7%
ROC
0.08%
Gross Margin
70%
Oper. Margin
12%
Profit Margin
11%
Payout
49%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
22.96-41.3
52W High
-32.66%
52W Low
+25.5%
RSI
42
Rel Volume
0.34
Avg Volume
3.18M
Volume
1.09M
Perf Week
-0.4%
Perf Month
-11.9%
Perf Quarter
19.68%
Perf Half Y
12.6%
-
-
-
-
Beta
0.225
-
-
Volatility
0.3%, 1.34%
Prev Close
-0.83%
Price
27.61
Change
-0.4%
603983.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.36 | 4.49 | 4.35 | 4.46 | 4.32 | |
| Net income per share | 1.15 | 1.28 | 1.16 | 0.62 | 0.43 | |
| Operating cash flow per share | 1.43 | 1.16 | 0.9 | -0.02 | 0.12 | |
| Free cash flow per share | 1.4 | 1.14 | -0.96 | -0.31 | -0.16 | |
| Cash per share | 4.33 | 7.23 | 6.21 | 3.85 | 3.77 | |
| Book value per share | 3.81 | 6.66 | 7.43 | 7.69 | 7.95 | |
| Tangible book value per share | 3.75 | 6.61 | 7.44 | 5.97 | 6.24 | |
| Share holders equity per share | 3.81 | 6.66 | 7.43 | 7.69 | 7.95 | |
| Interest debt per share | 0.02 | -0.69 | 0.27 | 0.05 | 0.68 | |
| Market cap | 10.68B | 24.07B | 20.94B | 12.78B | 13.53B | |
| Enterprise value | 9.12B | 21.97B | 19.37B | 11.99B | 12.73B | |
| P/E ratio | 25.72 | 46.75 | 45.08 | 51.55 | 77.68 | |
| Price to sales ratio | 6.78 | 13.37 | 12 | 7.15 | 7.81 | |
| POCF ratio | 20.67 | 51.71 | 57.78 | -1.71K | 279.33 | |
| PFCF ratio | 21.14 | 52.43 | -54.16 | -102.55 | -216.57 | |
| P/B Ratio | 7.77 | 9.02 | 7.03 | 4.14 | 4.24 | |
| PTB ratio | 7.77 | 9.02 | 7.03 | 4.14 | 4.24 | |
| EV to sales | 5.79 | 12.2 | 11.1 | 6.71 | 7.35 | |
| Enterprise value over EBITDA | 19.29 | 34.46 | 32.85 | 35.02 | 52.45 | |
| EV to operating cash flow | 17.65 | 47.19 | 53.47 | -1.6K | 262.76 | |
| EV to free cash flow | 18.04 | 47.85 | -50.12 | -96.24 | -203.73 | |
| Earnings yield | 0.04 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Free cash flow yield | 0.05 | 0.02 | -0.02 | -0.01 | 0 | |
| Debt to equity | 0 | -0.1 | 0.04 | 0.01 | 0.08 | |
| Debt to assets | 0 | -0.08 | 0.03 | 0.01 | 0.07 | |
| Net debt to EBITDA | -3.31 | -3.3 | -2.65 | -2.3 | -3.31 | |
| Current ratio | 2.52 | 4.23 | 3.41 | 3.43 | 3.35 | |
| Interest coverage | 65.14 | 0 | 504.71 | 292.06 | 63.99 | |
| Income quality | 1.25 | 0.91 | 0.78 | -0.03 | 0.29 | |
| Dividend Yield | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0 | 0 | 0.34 | 0.57 | 0.44 | |
| Sales general and administrative to revenue | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.01 | 0.01 | 0 | 0.2 | 0.18 | |
| Capex to operating cash flow | -0.02 | -0.01 | -2.07 | 15.66 | -2.29 | |
| Capex to revenue | -0.01 | 0 | -0.43 | -0.07 | -0.06 | |
| Capex to depreciation | -0.77 | -0.41 | -59.22 | -5.83 | -4.18 | |
| Stock based compensation to revenue | 0 | 0 | 0 | -0.01 | 0.01 | |
| Graham number | 9.93 | 13.87 | 13.91 | 10.34 | 8.81 | |
| ROIC | 0.3 | 0.21 | 0.15 | 0.07 | 0.05 | |
| Return on tangible assets | 0.2 | 0.15 | 0.12 | 0.08 | 0.05 | |
| Graham Net | 2.52 | 5.6 | 4.48 | 2.72 | 2.05 | |
| Working capital | 1.08B | 2.39B | 1.9B | 1.4B | 1.57B | |
| Tangible asset value | 1.35B | 2.65B | 2.98B | 2.39B | 2.5B | |
| Net current asset value | 1.06B | 2.36B | 1.89B | 1.37B | 1.4B | |
| Invested capital | 0 | -0.1 | 0.04 | 0.01 | 0.08 | |
| Average receivables | 44.67M | 24.26M | 33.98M | 73.67M | 103.07M | |
| Average payables | 244.66M | 281.58M | 271.34M | 225.64M | 214.12M | |
| Average inventory | 120.85M | 158.06M | 162.66M | 138.36M | 145.06M | |
| Days sales outstanding | 5.05 | 5.42 | 8.63 | 21.67 | 21.08 | |
| Days payables outstanding | 199.97 | 184.45 | 156.51 | 112.61 | 153.28 | |
| Days of inventory on hand | 94.43 | 119.04 | 85.59 | 78.58 | 101.17 | |
| Receivables turnover | 72.35 | 67.36 | 42.32 | 16.84 | 17.31 | |
| Payables turnover | 1.83 | 1.98 | 2.33 | 3.24 | 2.38 | |
| Inventory turnover | 3.87 | 3.07 | 4.26 | 4.65 | 3.61 | |
| ROE | 0.3 | 0.19 | 0.16 | 0.08 | 0.05 | |
| Capex per share | -0.03 | -0.02 | -1.87 | -0.29 | -0.28 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.83 | 1.47 | 1.19 | 1.45 | 1.19 | |
| Net income per share | 0 | 0.14 | 0.2 | 0.13 | 0.11 | |
| Operating cash flow per share | 0 | 0.14 | 0.2 | 0.31 | -0.02 | |
| Free cash flow per share | -0.11 | 0.12 | 0.11 | 0.01 | -0.15 | |
| Cash per share | 3.45 | 3.77 | 3.7 | 3.73 | 3.1 | |
| Book value per share | 7.96 | 7.95 | 8.15 | 8.03 | 8.13 | |
| Tangible book value per share | 6.21 | 6.24 | 6.45 | 6.33 | 6.45 | |
| Share holders equity per share | 7.96 | 7.95 | 8.15 | 8.03 | 8.13 | |
| Interest debt per share | 0.07 | 0.68 | 0.92 | 0.92 | 0.66 | |
| Market cap | 10.21B | 13.53B | 15.3B | 12.97B | 9.91B | |
| Enterprise value | 9.32B | 12.73B | 14.55B | 12.22B | 9.31B | |
| P/E ratio | 1.82K | 62.44 | 48.62 | 62.35 | 57.44 | |
| Price to sales ratio | 31.28 | 23.01 | 32.09 | 22.26 | 20.78 | |
| POCF ratio | 7.27K | 249.75 | 194.46 | 105.36 | -1.04K | |
| PFCF ratio | -244.16 | 292.82 | 346.27 | 4.61K | -160.87 | |
| P/B Ratio | 3.27 | 4.24 | 4.68 | 4.03 | 3.04 | |
| PTB ratio | 3.27 | 4.24 | 4.68 | 4.03 | 3.04 | |
| EV to sales | 28.55 | 21.64 | 30.52 | 20.97 | 19.51 | |
| Enterprise value over EBITDA | 763.07 | 201.82 | 146.08 | 173.63 | 294.65 | |
| EV to operating cash flow | 6.64K | 234.93 | 184.93 | 99.23 | -974.06 | |
| EV to free cash flow | -222.83 | 275.45 | 329.3 | 4.34K | -151.06 | |
| Earnings yield | 0 | 0 | 0.01 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | -0.01 | |
| Debt to equity | 0.01 | 0.08 | 0.11 | 0.11 | 0.08 | |
| Debt to assets | 0.01 | 0.07 | 0.09 | 0.09 | 0.07 | |
| Net debt to EBITDA | -73.06 | -12.73 | -7.53 | -10.73 | -19.14 | |
| Current ratio | 3.43 | 3.35 | 2.82 | 2.44 | 2.9 | |
| Interest coverage | 6.53 | 64.13 | 73.16 | 37.28 | 11.69 | |
| Income quality | 1 | 1 | 1 | 2.37 | -0.22 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0.01 | |
| Payout ratio | 49.68 | 0.13 | 0.02 | 0.02 | 2.35 | |
| Sales general and administrative to revenue | 0.19 | -0.06 | 0.04 | -0.01 | 0.12 | |
| Research and developement to revenue | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.2 | 0.18 | 0.18 | 0.17 | 0.18 | |
| Capex to operating cash flow | -30.79 | -0.15 | -0.44 | -0.98 | 5.45 | |
| Capex to revenue | -0.13 | -0.01 | -0.07 | -0.21 | -0.11 | |
| Capex to depreciation | -5.16 | -0.95 | -4.86 | -16.96 | 6.2 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0 | |
| Graham number | 0.8 | 4.92 | 6 | 4.84 | 4.44 | |
| ROIC | 0 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Return on tangible assets | 0 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Graham Net | 2.39 | 2.05 | 2.08 | 1.79 | 1.73 | |
| Working capital | 1.31B | 1.57B | 1.47B | 1.36B | 1.35B | |
| Tangible asset value | 2.44B | 2.5B | 2.59B | 2.54B | 2.59B | |
| Net current asset value | 1.28B | 1.4B | 1.45B | 1.35B | 1.33B | |
| Invested capital | 0.01 | 0.08 | 0.11 | 0.11 | 0.08 | |
| Average receivables | 127.93M | 105.87M | 121.79M | 149.37M | 140.18M | |
| Average payables | 227.9M | 244.96M | 200.59M | 204.93M | 228.89M | |
| Average inventory | 130.51M | 144.6M | 143.9M | 135.85M | 152.28M | |
| Days sales outstanding | 30.79 | 15.31 | 27.1 | 23.97 | 23.62 | |
| Days payables outstanding | 204.23 | 114.26 | 103.27 | 128.4 | 150.12 | |
| Days of inventory on hand | 107.98 | 75.41 | 82.03 | 73 | 115.67 | |
| Receivables turnover | 2.92 | 5.88 | 3.32 | 3.75 | 3.81 | |
| Payables turnover | 0.44 | 0.79 | 0.87 | 0.7 | 0.6 | |
| Inventory turnover | 0.83 | 1.19 | 1.1 | 1.23 | 0.78 | |
| ROE | 0 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Capex per share | -0.11 | -0.02 | -0.09 | -0.3 | -0.13 |
603983.SS Frequently Asked Questions
What is Guangdong Marubi Biotechnology Co., Ltd. stock symbol ?
Guangdong Marubi Biotechnology Co., Ltd. is a CN stock and trading under the symbol 603983.SS
What is Guangdong Marubi Biotechnology Co., Ltd. stock quote today ?
Guangdong Marubi Biotechnology Co., Ltd. stock price is $27.61 today.
Is Guangdong Marubi Biotechnology Co., Ltd. stock public?
Yes, Guangdong Marubi Biotechnology Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 3.18M
- Market Capitalization 11.02B
- Employee 1.06K
- CEO Mr. Huaiqing Sun
- Headquarters Guangzhou,CN
- IPO Date 2019-07-25
-
Website
https://www.marubi.cn 
Guangdong Marubi Biotechnology Co., Ltd. provides eye care product in China. It engages in the research and development, design, production, and sales of various cosmetic products based on skin science and biological science research. The company offers its products under the Marumi, Chunji, and Lianhuo brand names. Guangdong Marubi Biotechnology Co., Ltd. was founded in 2002 and is based in Guangzhou, China.
